September 19, 2019
Add to Twitter
English | عربي
New Data from Esketamine Nasal Spray Phase 3 Studies Showed Rapid Reduction of Depressive Symptoms in Adult Patients with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
Global clinical programme is the first to study this severely ill patient population, who are typically excluded from antidepressant treatment studies